Kintara Therapeutics Inc (NASDAQ:KTRA)

North American company
add to virtual portfolio
trade
This share can be held in
Trading AccountISAJISASIPP

Share Price Chart

- Chart currently unavailable -

Market Info - KTRA

  • Market Open Price0.00
  • Previous Close0.00
  • Volume-
  • 52w Low/High-
  • Last Trade Price0.00
  • Bid/Ask Price0.00

Company Info - KTRA

  • Market Cap$40.940m
  • SymbolNASDAQ:KTRA
  • IndustryHealthcare
  • SectorBiotechnology
  • Currency
  • ISINUS49720K1016

Company Profile

Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian, and other solid tumors. The company is also advancing its proprietary late stage photodynamic therapy (PDT) platform that holds promise as a localized cutaneous or visceral tumor treatment as well as in other potential indications.DelMar Pharmaceuticals Inc is a clinical stage drug development company. It is engaged in research and development of cancer indications.

Latest KTRA news

Currently there for this company. Visit our news hub for other news .